Company Profile
Neurokos, Inc. is a privately held, clinical stage, biopharmaceutical company, committed to developing first-in-class therapies for
CNS disorders. Our goal is to be a leader in the research and development of novel drugs that address unmet patient needs.
Neurodegenerative diseases are Neurokos' first area of focus. Our active development pipeline comprises multiple programs addressing
Alzheimer's disease and Cerebral Amyloid Angiopathy among other degenerative diseases of the brain. Our programs include clinical stage
candidates in addition to pre-clinical and discovery stage opportunities.
Our strong intellectual property portfolio includes several granted and filed, global patents along with exclusive licenses to patents based on over
three decades of work by our partners.
Neurodegenerative diseases are Neurokos' first area of focus. Our active development pipeline comprises multiple programs addressing Alzheimer's disease and Cerebral Amyloid Angiopathy among other degenerative diseases of the brain. Our programs include clinical stage candidates in addition to pre-clinical and discovery stage opportunities.